Literature DB >> 3986805

Relation of estrogen receptor expression to clonal growth and antiestrogen effects on human breast cancer cells.

F Kodama, G L Greene, S E Salmon.   

Abstract

Expression of estrogen receptor (ER) was studied in the ER-positive human breast cancer cell line MCF-7 using immunoperoxidase staining with monoclonal antibodies to ER. Using a soft agar colony assay and liquid culture, effects of growth and the antiestrogen tamoxifen were examined. Heterogeneity in expression of ER was observed between different clones in the agar cultures as well as among cells within the same clone. Clonal expression of ER increased progressively with increasing cell number within a clone. At pharmacological doses, tamoxifen significantly reduced clonal growth but also markedly reduced the expression of ER within clones that grew despite the presence of the antiestrogen. These findings are consistent with the hypothesis that ER-positive colonies arise from ER-negative progenitors and that ER expression occurs along with differentiation of cells within clones. Furthermore, the findings are consistent with tamoxifen exerting its antineoplastic action beyond the level of the tumor stem cell. Such therapy would therefore be capable of suppression but not eradication of breast cancer clonal progenitors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3986805

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Estrogen responsiveness and control of normal human breast proliferation.

Authors:  E Anderson; R B Clarke; A Howell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

2.  Prognostic significance of steroid hormone receptors and histopathological characterization of human breast cancer.

Authors:  A Reiner; R Kolb; G Reiner; R Jakesz; M Schemper; J Spona
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Oestrogen receptor activity in intraduct and invasive breast carcinomas.

Authors:  R A Hawkins; A L Tesdale; W A Ferguson; J J Going
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

4.  Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  A Reiner; J Spona; G Reiner; M Schemper; R Kolb; W Kwasny; R Függer; R Jakesz; J H Holzner
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

5.  Hypotheses: melatonin/steroid combination contraceptives will prevent breast cancer.

Authors:  M Cohen; R A Small; A Brzezinski
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

6.  Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles.

Authors:  Sonia Javan Moghadam; Amanda M Hanks; Khandan Keyomarsi
Journal:  J Carcinog       Date:  2011-11-30

7.  17Beta-estradiol suppresses TLR3-induced cytokine and chemokine production in endometrial epithelial cells.

Authors:  Margaret J Lesmeister; Rebecca L Jorgenson; Steven L Young; Michael L Misfeldt
Journal:  Reprod Biol Endocrinol       Date:  2005-12-29       Impact factor: 5.211

8.  Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor.

Authors:  R Piva; A P Rimondi; S Hanau; I Maestri; A Alvisi; V L Kumar; L del Senno
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

9.  Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas.

Authors:  G Cattoretti; S Andreola; C Clemente; L D'Amato; F Rilke
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

10.  Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

Authors:  D J DeFriend; E Anderson; J Bell; D P Wilks; C M West; R E Mansel; A Howell
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.